// App-Quantinova.ai

: Exacerbation risk after night-time waking due to asthma in SYGMA 1

Researchers

Presenter

  • Helen Reddel

Principal Investigators

  • Eric D. Bateman

  • J. Mark Fitzgerald

  • Peter J. Barnes

  • Nanshan Zhong

  • Rosa Lamarca

  • Margareta Puu

  • Vijay Alagappan

  • Glenn Whelan

  • Paul M. OByrne

Medical Centers

  • Woolcock Institute of Medical Research, University of Sydney, Sydney, Australia.

  • University of Cape Town, Cape Town, South Africa

  • Institute for Heart and Lung Health, University of British Columbia, Vancouver, BC, Canada,

  • Airway Disease Infection Section, National Heart and Lung Institute (NHLI), Imperial College London, London, United Kingdom.

  • State Key Laboratory of Respiratory Diseases, First Affiliated Hospital, Guangzhou Medical University, Guangzhou, China,

  • AstraZeneca, Barcelona, Spain.

  • AstraZeneca, Gothenburg, Sweden

  • AstraZeneca Gaithersburg, Gaithersburg, United States of America

  • Firestone Institute for Respiratory Health, St Joseph’s Healthcare and Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada,

Locations

  • Australia

  • South Africa

  • Canada

  • United Kingdom

  • China

  • Spain

  • Sweden

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Asthma

Biomarkers

  • N/A

Drug/Treatment

  • Terbutaline

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • NA

Study Id's

  • NCT02149199

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved